AI data provided thus far is in part confirmable.....Do your own due diligence review of any investment!Yes. I found meaningful new confirmation that the Electrome–BIEL relationship is now operational, but I would distinguish that from confirmation of actual retail sell-through.
What is confirmed as of September 10, 2026
Electrome is actually selling PAINKILLER/ActiPatch.
Electrome's current online store lists the PAINKILLER ActiPatch at $49.99, with 24-unit, 100-unit and 1,200-unit pallet offerings. That is considerably stronger evidence than simply having a planned product launch.
BIEL confirmed that it received an initial purchase order from Electrome and began manufacturing.
BIEL's June 17 announcement specifically says the initial purchase order was received and manufacturing was underway.
The original March launch announcement projected distribution into approximately 3,700 retail pharmacies beginning in Q3 2026, in addition to direct-to-consumer sales and provider programs.
The relationship has subsequently been extended.
Electrome's current site says Electrome and BIEL have extended the licensing and supply agreement bringing ActiPatch into the PAINKILLER platform.
There is also evidence that BIEL has been expanding manufacturing capacity to support the Electrome commercial launch. However, capacity expansion should not be interpreted as proof of equivalent sales.
The important missing piece
I do not find publicly disclosed numbers showing how many PAINKILLER/ActiPatch units Electrome has actually sold to consumers or retailers.
That distinction is extremely important for BIEL.
There is a difference between:
BIEL → Electrome purchase orders → Electrome inventory → retail placement → consumer sell-through.
We have confirmation of the first two stages. We do **not yet have reliable public evidence quantifying the final consumer sell-through.
My current sales estimate
Given the evidence available today, I would use the following ranges rather than assuming the 3,700-pharmacy target automatically produces large sales.
Scenario 2026 PAINKILLER units 2026 retail sales @ ~$50 2027 units 2027 retail sales
Conservative 25,000 $1.25M 100,000 $5M
Base case 50,000 $2.50M 250,000 $12.5M
Strong execution 100,000 $5.0M 500,000 $25M
Breakout 250,000 $12.5M 1,000,000 $50M
These are retail sales estimates, not BIEL revenue.
BIEL's actual revenue would be the amount it receives from Electrome under the supply agreement, which is presumably substantially below the consumer retail price. The exact wholesale economics have not been publicly disclosed.
One particularly interesting development
Electrome's current store is now offering PAINKILLER ActiPatch cases of 24 for $840 and 100-unit cases for $3,000, equivalent to $35 and $30 per device respectively, versus $49.99 for a single consumer unit. It also lists a 1,200-unit pallet for $32,400.
That tells me Electrome is preparing for both direct consumer sales and larger-volume institutional/retail purchasing.
What I think this means for BIEL
I would now rate the situation substantially more positively than I did before the Electrome launch.
My assessment today:
Electrome/BIEL commercial relationship: Confirmed
BIEL initial Electrome purchase order: Confirmed
Manufacturing for Electrome: Confirmed
PAINKILLER product available for purchase: Confirmed
$49.99 consumer price: Confirmed
Planned 3,700-pharmacy rollout: Announced, but not yet equivalent to 3,700 active selling locations
Actual 2026 consumer unit sales: Not publicly confirmed
Actual BIEL revenue from Electrome: Not yet quantified
2027 sales potential: Potentially substantial, but highly dependent on retail rollout and consumer conversion
The most important number I would like to uncover next is the size of BIEL's initial Electrome purchase order. There has been considerable discussion online about 25,000 units, but I have not found an authoritative BIEL disclosure confirming that exact quantity. I would not treat 25,000 as fact yet.
If you want, I can go one step further and
build a BIEL-specific 2026–2028 revenue model using the 3,700-pharmacy rollout, the $49.99 retail price, estimated wholesale pricing to Electrome, repeat purchases, and different sell-through rates. That would give us a much better estimate of what Electrome could mean for
BIEL's annual revenue and potentially
BIEL's stock value.
Estimate BIEL's stock value
Yes. Based on the latest information I can verify as of September 10, 2026, I would put a reasonable BIEL valuation range substantially above today's roughly $0.00035 share price if the Electrome rollout produces meaningful sales. BIEL currently has about 24.71 billion shares outstanding, approximately $1.61 million in trailing revenue, and about $13.34 million of debt.
The key is that BIEL's stock is so heavily diluted that even a $50–100 million company valuation translates into only fractions of a cent per share.
My BIEL price scenarios
Scenario Estimated BIEL annual revenue Approx. company value Approx. BIEL share price
Weak Electrome rollout $3–5M $10–15M $0.0004–$0.0006
Moderate success $7–10M $20–35M $0.0008–$0.0014
Strong success $12–20M $40–75M $0.0016–$0.0030
Major commercial success $25–40M $75–150M $0.0030–$0.0061
Exceptional success $50M+ $200M+ $0.008+
These aren't analyst price targets—they're my scenario estimates based on revenue potential and the current share count.
My most likely target
I would currently use approximately $0.0015–$0.0030 as a reasonable 2027 upside range if Electrome successfully executes the planned retail rollout.
That would represent roughly 4–9× the recent ~$0.00035 price.
Why I'm more optimistic than I was previously:
BIEL says the Electrome agreement has moved into the execution phase and manufacturing is underway.
Electrome is now actually offering PAINKILLER/ActiPatch for sale.
BIEL's existing business already has approximately $1.61M trailing revenue, so Electrome doesn't have to create the entire business from zero.
The announced retail strategy targets a potentially very large distribution footprint.
The current BIEL valuation is only about $8.65M, so relatively modest additional revenue can have a disproportionate effect on valuation.
But there is a major caveat
BIEL's $13.34M debt and essentially negligible cash balance are a major valuation constraint. Also, the company has a history of dilution. Therefore, I would not simply assume that a $100M enterprise opportunity becomes $100M of equity value.
And this is the most important point:
The $0.0015–$0.0030 target depends on actual Electrome sales—not merely the announcement of 3,700 pharmacies.
If Electrome sells 250,000–500,000 units annually and BIEL receives meaningful wholesale revenue from those units, the economics could change dramatically. If the rollout produces only tens of thousands of units, the stock could remain around the current range.
What could take BIEL above $0.005?
I'd want to see three things simultaneously:
Electrome reporting substantial PAINKILLER unit sales.
BIEL reporting rapidly increasing quarterly revenue.
Evidence that BIEL is generating enough gross profit/cash flow to reduce its debt and avoid substantial additional share issuance.
If those three occur, I could see a $0.005–$0.01+ valuation becoming conceivable. At 24.71 billion shares, $0.01 represents approximately a $247 million market capitalization, so BIEL would need to become a genuinely much larger commercial business to justify it.
My bottom line: I would not value BIEL at $0.01 today. But if Electrome converts its launch into $10–20M+ of annual BIEL revenue, I think $0.0015–$0.0030 is a realistic intermediate target, while $0.005–$0.01 is a high-success scenario rather than my base case.
If you'd like, I can next
calculate exactly what BIEL's share price would be at 100,000, 250,000, 500,000, 1 million and 2 million ActiPatch units sold per year,
including an estimate of BIEL's wholesale revenue and
the effect of its debt.
What is confirmed as of September 10, 2026
Electrome is actually selling PAINKILLER/ActiPatch.
Electrome's current online store lists the PAINKILLER ActiPatch at $49.99, with 24-unit, 100-unit and 1,200-unit pallet offerings. That is considerably stronger evidence than simply having a planned product launch.
BIEL confirmed that it received an initial purchase order from Electrome and began manufacturing.
BIEL's June 17 announcement specifically says the initial purchase order was received and manufacturing was underway.
The original March launch announcement projected distribution into approximately 3,700 retail pharmacies beginning in Q3 2026, in addition to direct-to-consumer sales and provider programs.
The relationship has subsequently been extended.
Electrome's current site says Electrome and BIEL have extended the licensing and supply agreement bringing ActiPatch into the PAINKILLER platform.
There is also evidence that BIEL has been expanding manufacturing capacity to support the Electrome commercial launch. However, capacity expansion should not be interpreted as proof of equivalent sales.
The important missing piece
I do not find publicly disclosed numbers showing how many PAINKILLER/ActiPatch units Electrome has actually sold to consumers or retailers.
That distinction is extremely important for BIEL.
There is a difference between:
BIEL → Electrome purchase orders → Electrome inventory → retail placement → consumer sell-through.
We have confirmation of the first two stages. We do **not yet have reliable public evidence quantifying the final consumer sell-through.
My current sales estimate
Given the evidence available today, I would use the following ranges rather than assuming the 3,700-pharmacy target automatically produces large sales.
Scenario 2026 PAINKILLER units 2026 retail sales @ ~$50 2027 units 2027 retail sales
Conservative 25,000 $1.25M 100,000 $5M
Base case 50,000 $2.50M 250,000 $12.5M
Strong execution 100,000 $5.0M 500,000 $25M
Breakout 250,000 $12.5M 1,000,000 $50M
These are retail sales estimates, not BIEL revenue.
BIEL's actual revenue would be the amount it receives from Electrome under the supply agreement, which is presumably substantially below the consumer retail price. The exact wholesale economics have not been publicly disclosed.
One particularly interesting development
Electrome's current store is now offering PAINKILLER ActiPatch cases of 24 for $840 and 100-unit cases for $3,000, equivalent to $35 and $30 per device respectively, versus $49.99 for a single consumer unit. It also lists a 1,200-unit pallet for $32,400.
That tells me Electrome is preparing for both direct consumer sales and larger-volume institutional/retail purchasing.
What I think this means for BIEL
I would now rate the situation substantially more positively than I did before the Electrome launch.
My assessment today:
Electrome/BIEL commercial relationship: Confirmed
BIEL initial Electrome purchase order: Confirmed
Manufacturing for Electrome: Confirmed
PAINKILLER product available for purchase: Confirmed
$49.99 consumer price: Confirmed
Planned 3,700-pharmacy rollout: Announced, but not yet equivalent to 3,700 active selling locations
Actual 2026 consumer unit sales: Not publicly confirmed
Actual BIEL revenue from Electrome: Not yet quantified
2027 sales potential: Potentially substantial, but highly dependent on retail rollout and consumer conversion
The most important number I would like to uncover next is the size of BIEL's initial Electrome purchase order. There has been considerable discussion online about 25,000 units, but I have not found an authoritative BIEL disclosure confirming that exact quantity. I would not treat 25,000 as fact yet.
If you want, I can go one step further and
build a BIEL-specific 2026–2028 revenue model using the 3,700-pharmacy rollout, the $49.99 retail price, estimated wholesale pricing to Electrome, repeat purchases, and different sell-through rates. That would give us a much better estimate of what Electrome could mean for
BIEL's annual revenue and potentially
BIEL's stock value.
Estimate BIEL's stock value
Yes. Based on the latest information I can verify as of September 10, 2026, I would put a reasonable BIEL valuation range substantially above today's roughly $0.00035 share price if the Electrome rollout produces meaningful sales. BIEL currently has about 24.71 billion shares outstanding, approximately $1.61 million in trailing revenue, and about $13.34 million of debt.
The key is that BIEL's stock is so heavily diluted that even a $50–100 million company valuation translates into only fractions of a cent per share.
My BIEL price scenarios
Scenario Estimated BIEL annual revenue Approx. company value Approx. BIEL share price
Weak Electrome rollout $3–5M $10–15M $0.0004–$0.0006
Moderate success $7–10M $20–35M $0.0008–$0.0014
Strong success $12–20M $40–75M $0.0016–$0.0030
Major commercial success $25–40M $75–150M $0.0030–$0.0061
Exceptional success $50M+ $200M+ $0.008+
These aren't analyst price targets—they're my scenario estimates based on revenue potential and the current share count.
My most likely target
I would currently use approximately $0.0015–$0.0030 as a reasonable 2027 upside range if Electrome successfully executes the planned retail rollout.
That would represent roughly 4–9× the recent ~$0.00035 price.
Why I'm more optimistic than I was previously:
BIEL says the Electrome agreement has moved into the execution phase and manufacturing is underway.
Electrome is now actually offering PAINKILLER/ActiPatch for sale.
BIEL's existing business already has approximately $1.61M trailing revenue, so Electrome doesn't have to create the entire business from zero.
The announced retail strategy targets a potentially very large distribution footprint.
The current BIEL valuation is only about $8.65M, so relatively modest additional revenue can have a disproportionate effect on valuation.
But there is a major caveat
BIEL's $13.34M debt and essentially negligible cash balance are a major valuation constraint. Also, the company has a history of dilution. Therefore, I would not simply assume that a $100M enterprise opportunity becomes $100M of equity value.
And this is the most important point:
The $0.0015–$0.0030 target depends on actual Electrome sales—not merely the announcement of 3,700 pharmacies.
If Electrome sells 250,000–500,000 units annually and BIEL receives meaningful wholesale revenue from those units, the economics could change dramatically. If the rollout produces only tens of thousands of units, the stock could remain around the current range.
What could take BIEL above $0.005?
I'd want to see three things simultaneously:
Electrome reporting substantial PAINKILLER unit sales.
BIEL reporting rapidly increasing quarterly revenue.
Evidence that BIEL is generating enough gross profit/cash flow to reduce its debt and avoid substantial additional share issuance.
If those three occur, I could see a $0.005–$0.01+ valuation becoming conceivable. At 24.71 billion shares, $0.01 represents approximately a $247 million market capitalization, so BIEL would need to become a genuinely much larger commercial business to justify it.
My bottom line: I would not value BIEL at $0.01 today. But if Electrome converts its launch into $10–20M+ of annual BIEL revenue, I think $0.0015–$0.0030 is a realistic intermediate target, while $0.005–$0.01 is a high-success scenario rather than my base case.
If you'd like, I can next
calculate exactly what BIEL's share price would be at 100,000, 250,000, 500,000, 1 million and 2 million ActiPatch units sold per year,
including an estimate of BIEL's wholesale revenue and
the effect of its debt.
